Rheumatoid arthritis (RA) patients refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF targeted therapy (e.g., Bristol-Myers Squibb’s Orencia, Roche’s Actemra / RoActemra, Roche’s Rituxan / MabThera). The recent launch of AbbVie’s Rinvoq in the United States and Europe, along with Pfizer’s Xeljanz in Europe and Eli Lilly / Incyte’s Olumiant in both the United States and Europe, gives physicians more treatment options with a convenient route of administration (i.e., oral). The launch of an additional interleukin(IL)-6 inhibitor, Regeneron / Sanofi’s Kevzara, has further expanded the treatment armamentarium. Although the RA therapy market offers multiple efficacious and relatively safe agents, patients refractory to TNF-α inhibitors have limited options, even with the recent entry of newer agents; therefore, substantial unmet need remains in the treatment of tumor necrosis factor inhibitor (TNFi)-refractory RA.
- What are the treatment drivers and goals in TNFi-refractory RA?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What are the prevailing areas of unmet need and opportunity in TNFi-refractory RA?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new drug targeting TNFi-refractory RA?
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. rheumatologists and 30 European rheumatologists, fielded in January 2020
Key companies: Roche, Bristol-Myers Squibb, AbbVie, Pfizer, Eli Lilly, Incyte, Sanofi, Regeneron
Key drugs: Rituxan / MabThera, Orencia, Actemra / RoActemra, Xeljanz, Olumiant, Rinvoq
- Rheumatoid Arthritis - Unmet Need - Detailed, Expanded Analysis: TNF-alpha Refractory Rheumatoid Arthritis (US & EU )
Author(s): Prerna Sharma
Prerna Sharma is a senior analyst on the Immune and Inflammatory Disorders team at Decision Resources Group. She performs in-depth research to understand the rheumatology therapy area, specializing in rheumatoid arthritis, and creates disease landscape and forecast syndicated reports. Prior to joining DRG, she was a senior analyst at Evalueserve, where she fulfilled the research and market requirements of global pharmaceutical companies in creating syndicated and nonsyndicated reports detailing disease landscapes. Ms. Sharma has expertise in creating market assessments, competitive intelligence reports, and in-depth company profiles for the pharmaceutical and consumer healthcare sectors. She graduated from Amity University in India with a bachelor’s degree in biotechnology.